OBIZUR
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- OBIZUR
- Generic name
- ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- a69ccbb3-7648-4978-8c6d-7ca6b95a9b01
- SPL ID
- 181004b3-db8d-4be1-a47d-604fd0cff078
- Version
- 18
- Effective date
- 2025-03-05
- Source export date
- 2026-11-13
- Source partition
- 14
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0014-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/087e7a9c7af51c6b12a0e8fd611a27cb8635e1910ad160b89995da9a4b39b1b3/drug-label-0014-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 18:18:22
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125512 | derived:openfda.application_number |
| application number | BLA125512 | openfda.application_number | |
| brand name | OBIZUR | openfda.brand_name | |
| generic name | ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE | openfda.generic_name | |
| manufacturer name | Takeda Pharmaceuticals America, Inc. | openfda.manufacturer_name | |
| ndc | package | 0944-5011-01 | openfda.package_ndc |
| ndc | package | 0944-5001-01 | openfda.package_ndc |
| ndc | package | 0944-0011-01 | openfda.package_ndc |
| ndc | product | 0944-5001 | openfda.product_ndc |
| ndc11 | package | 00944500101 | derived:openfda.package_ndc |
| ndc11 | package | 00944001101 | derived:openfda.package_ndc |
| ndc11 | package | 00944501101 | derived:openfda.package_ndc |
| rxcui | 1593156 | openfda.rxcui | |
| rxcui | 1593154 | openfda.rxcui | |
| spl id | 181004b3-db8d-4be1-a47d-604fd0cff078 | id | |
| spl set id | a69ccbb3-7648-4978-8c6d-7ca6b95a9b01 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, may occur. Should symptoms occur, discontinue OBIZUR and administer appropriate treatment. ( 5.1 ) Development of inhibitory antibodies to OBIZUR has occurred and may result in a lack of efficacy. ( 5.2 ) Anamnestic reactions with rise in human factor VIII and/or recombinant factor VIII, porcine sequence inhibitors have occurred and may result in a lack of efficacy. ( 5.2 ) Consider evaluating for presence of anti-recombinant porcine factor VIII (anti-rpFVIII) antibodies prior to initiation of treatment with OBIZUR. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures porcine factor VIII inhibitor concentration. In instances where positive anti-rpFVIII antibody results are detected after treatment with OBIZUR is initiated, factor VIII levels may be used to decide whether treatment with OBIZUR should be continued. ( 5.2 ) ( 5.3 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions can occur with OBIZUR. OBIZUR contains trace amounts of hamster proteins. Early signs of allergic reactions, which can progress to anaphylaxis, include angioedema, chest-tightness, dyspnea, hypotension, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if allergic or anaphylactic-type reactions occur. 5.2 Inhibitory Antibodies Inhibitory antibodies to OBIZUR have occurred in patients treated with OBIZUR. Lack of efficacy could be due to inhibitory antibodies to OBIZUR. Anamnestic reactions with rise in human factor VIII and/or recombinant factor VIII, porcine sequence inhibitors have also been reported in patients treated with OBIZUR. These anamnestic rises also may result in lack of efficacy. Consider evaluating for presence of anti-recombinant porcine factor VIII (anti-rpFVIII) antibodies prior to initiation of treatment with OBIZUR. In instances where positive anti-rpFVIII antibody results are detected after treatment with OBIZUR is initiated, factor VIII levels may be used to decide whether treatment with OBIZUR should be continued [see Warnings and Precautions (5.3) ] . Monitor patients for the development of antibodies to OBIZUR by appropriate assays [see Warnings and Precautions (5.3) ] . If the plasma factor VIII level fails to increase as expected, or if bleeding is not controlled after OBIZUR administration, suspect the presence of an anti-porcine factor VIII antibody. If such inhibitory antibodies are suspected and there is a lack of efficacy, consider management options such as discontinuing OBIZUR and initiating other therapeutics such as a Factor VIII bypassing agent. 5.3 Monitoring Laboratory Tests Perform one-stage clotting assay to confirm that adequate factor VIII levels have been achieved and maintained [see Dosage and Administration (2) ] . Monitor factor VIII activity 30 minutes and 3 hours after initial dose. Monitor factor VIII activity 30 minutes after subsequent doses. Monitor the development of inhibitory antibodies to OBIZUR. Perform a Nijmegen Bethesda inhibitor assay with recombinant porcine factor VIII as substrate for recombinant porcine factor VIII antibodies if expected plasma factor VIII activity levels are not attained or if bleeding is not controlled with the expected dose of OBIZUR. Use Bethesda Units (BU) to report inhibitor levels. Contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) if additional information is needed regarding testing.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Common adverse reactions observed in greater than 5% of subjects in the clinical trial were development of inhibitors to porcine factor VIII. Common adverse reaction observed in greater than 5% of subjects in the clinical trial were development of inhibitors to porcine factor VIII. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction (AR) rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety and efficacy of OBIZUR was evaluated in a multi-center, prospective, open-label, clinical trial that investigated adult patients with acquired hemophilia A. Twenty-nine adult subjects were enrolled in the study, received at least one dose of OBIZUR and were evaluable for safety [see Clinical Studies (14) ] . Of the 29 adult subjects, 10 were between the ages of 42 and 65, and 19 were 65 years of age or older (18 Caucasian, 6 African-American, and 5 Asian). Ten (34%) subjects were female. Immunogenicity: Anti-Drug Antibody-Associated Adverse Reactions All subjects were monitored for development of inhibitory antibodies to OBIZUR using the Nijmegen modification of the Bethesda inhibitor assay. A subject was considered to have developed an OBIZUR inhibitor if the titer was ≥0.6 Bethesda Units (BU)/mL. Acquired Hemophilia A Of the 29 subjects treated with OBIZUR, 19 subjects were negative for anti-porcine factor VIII antibodies at baseline. Five of the 19 (26%) developed anti-porcine factor VIII antibodies following exposure to OBIZUR. Serious adverse drug reactions (ADRs) occurred in 9 subjects. Two subjects (6.9%) developed anti-porcine FVIII inhibitors (≥0.6 Bethesda Units). Seven subjects (24.1%) developed anamnestic reactions with a rise ≥10 BU in human factor VIII and/or recombinant factor VIII, porcine sequence inhibitors. At 24 hours after initial dose, OBIZUR was effective in 9/10 patients with baseline anti-porcine antibodies (and partially effective in 1/10 patients) and was effective in all 5 with de novo anti-porcine antibodies. All subjects were also monitored for development of binding antibodies to baby hamster kidney (BHK) protein by a validated sequential ELISA (enzyme-linked immunosorbent assay). No patients developed de novo anti-BHK antibodies. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to OBIZUR with the incidence of antibodies to other products may be misleading. Congenital Hemophilia A with Inhibitors In the clinical study of OBIZUR in patients with congenital hemophilia A with FVIII inhibitors (CHAWI) undergoing surgery, out of 8 adult patients evaluable for safety analysis a total of 5 subjects experienced anamnestic reactions [see Contraindications (4) ] . A total of 5 (62.5%) subjects who underwent major surgeries reported anamnestic reactions with a rise ≥10 BU in human factor VIII and/or recombinant factor VIII, porcine sequence inhibitors ( see Table 2 ). 3 (37.5%) subjects developed anamnestic reactions to human Factor VIII (hFVIII) and porcine Factor VIII (pFVIII), 2 (25.0%) subjects developed anamnestic reactions to hFVIII. The highest increases in antibody levels reported are from 15.4 at baseline to 1039.6 BU for hFVIII and from 2.6 to 335.8 BU for pFVIII. Inhibitory antibodies may result in lack of efficacy. Table 2 Titer Levels of Subjects Experiencing Anamnestic Reactions Subjects hFVIII Inhibitors Titers (BU/mL) Obizur pFVIII Inhibitors Titers (BU/mL) Baseline Day 14 Visit End of the Study Visit Baseline Day 14 Visit End of the Study Visit Subject 1 1.3 1.2 (D3) 38.1/39.9 <0.6 <0.6 (D3) 29.3/38.8 Subject 2 15.4 1039.6 /807.9 2.6 0.7 (D5) 327.3/335.8 Subject 3 3.3 19.9 (D20) 23.3 5.6 36.1 (D20) 30.5 Subject 4 2.6 16.6 12.1 <0.6 1 0.9 Subject 5 4.6 3.8 (D3)/488 (D16) 336.3 1.7 <0.6 (D3)/285.9 (D16) 280.5
adverse reactions table
<table width="95%" ID="table2"><caption>Table 2 Titer Levels of Subjects Experiencing Anamnestic Reactions </caption><col width="14%" align="center" valign="middle"/><col width="10%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="16%" align="center" valign="middle"/><col width="10%" align="center" valign="middle"/><col width="17%" align="center" valign="middle"/><col width="16%" align="center" valign="middle"/><thead><tr><th rowspan="2" styleCode="Lrule Rrule">Subjects</th><th colspan="3" styleCode="Botrule Rrule">hFVIII Inhibitors Titers (BU/mL)</th><th colspan="3" styleCode="Botrule Rrule">Obizur pFVIII Inhibitors Titers (BU/mL)</th></tr><tr><th>Baseline </th><th>Day 14 Visit</th><th styleCode="Rrule">End of the Study Visit</th><th>Baseline</th><th>Day 14 Visit</th><th styleCode="Rrule">End of the Study Visit</th></tr></thead><tbody><tr><td styleCode="Lrule Rrule">Subject 1</td><td>1.3</td><td>1.2 (D3)</td><td styleCode="Rrule">38.1/39.9</td><td><0.6</td><td><0.6 (D3)</td><td styleCode="Rrule">29.3/38.8</td></tr><tr><td styleCode="Lrule Rrule">Subject 2</td><td>15.4</td><td/><td styleCode="Rrule">1039.6 /807.9</td><td>2.6</td><td>0.7 (D5)</td><td styleCode="Rrule">327.3/335.8</td></tr><tr><td styleCode="Lrule Rrule">Subject 3</td><td>3.3</td><td>19.9 (D20)</td><td styleCode="Rrule">23.3</td><td>5.6</td><td>36.1 (D20)</td><td styleCode="Rrule">30.5</td></tr><tr><td styleCode="Lrule Rrule">Subject 4</td><td>2.6</td><td>16.6</td><td styleCode="Rrule">12.1</td><td><0.6</td><td>1</td><td styleCode="Rrule">0.9</td></tr><tr><td styleCode="Lrule Rrule">Subject 5</td><td>4.6</td><td>3.8 (D3)/488 (D16)</td><td styleCode="Rrule">336.3</td><td>1.7</td><td><0.6 (D3)/285.9 (D16)</td><td styleCode="Rrule">280.5</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.